Mycenax Biotech Inc. (TPEX: 4726)

Mycenax Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	396.32	519.27	1,323	286.93	291.14	193.67
Short-Term Investments	7.3	148.42	16.12	-	-	83.56
Cash & Short-Term Investments	403.62	667.69	1,339	286.93	291.14	277.23
Cash Growth	-51.76%	-50.15%	366.84%	-1.45%	5.02%	-2.09%
Accounts Receivable	93.4	58.53	81.32	320.84	169.03	126.38
Other Receivables	4.38	4.69	3.09	11.33	5.51	1.83
Receivables	97.78	63.22	84.41	332.17	174.54	128.21
Inventory	73.33	112.33	246.72	173.3	84.85	56.12
Prepaid Expenses	81.03	83.25	103.22	89.28	23.82	24.24
Other Current Assets	172.09	171.53	149.95	15.73	2.16	9.15
Total Current Assets	827.84	1,098	1,924	897.41	576.51	494.96
Property, Plant & Equipment	1,758	1,847	1,978	1,351	786.73	592.84
Long-Term Investments	179.79	190.81	199.51	109.59	191.81	149.31
Goodwill	23.92	23.92	23.92	23.92	23.92	23.92
Other Intangible Assets	14.31	18.98	25.93	33.71	36.72	50.93
Long-Term Deferred Tax Assets	95.76	95.49	89.72	81.11	83.45	79.71
Other Long-Term Assets	578.24	495.85	211.93	642.46	53.41	16.33
Total Assets	3,478	3,770	4,453	3,139	1,753	1,408
Accounts Payable	55.64	44.05	52.52	54.68	40.31	24.7
Accrued Expenses	86.35	104.88	104.21	96.4	66.6	51.22
Short-Term Debt	-	-	100	50	100	-
Current Portion of Long-Term Debt	145.12	125.92	105.88	15.6	-	-
Current Portion of Leases	34.99	30.57	37.28	28.59	24.33	13.62
Current Income Taxes Payable	0.46	-	-	-	0.65	-
Current Unearned Revenue	222.95	187.28	142.28	152.12	125.9	91.69
Other Current Liabilities	98.6	260.72	92.57	142.69	66.99	50.69
Total Current Liabilities	644.1	753.42	634.73	540.07	424.78	231.92
Long-Term Debt	659.12	530.4	656.32	474.4	-	-
Long-Term Leases	77.9	39.39	56.37	176.06	72.28	33.18
Long-Term Deferred Tax Liabilities	-	-	-	3.75	6.68	3.81
Other Long-Term Liabilities	-	-	-	38.07	37.14	37.14
Total Liabilities	1,381	1,323	1,347	1,232	540.89	306.04
Common Stock	2,066	2,059	2,053	1,533	1,282	1,280
Additional Paid-In Capital	415.7	1,074	1,468	576.95	53.11	260.91
Retained Earnings	-383.84	-682.64	-406.83	-254.34	-207.23	-473.31
Comprehensive Income & Other	-1.37	-3.32	-8.8	50.72	83.41	34.81
Shareholders' Equity	2,097	2,447	3,106	1,907	1,212	1,102
Total Liabilities & Equity	3,478	3,770	4,453	3,139	1,753	1,408
Total Debt	917.12	726.28	955.85	744.64	196.61	46.8
Net Cash (Debt)	-513.5	-58.59	383.63	-457.72	94.53	230.43
Net Cash Growth	-	-	-	-	-58.98%	-18.62%
Net Cash Per Share	-2.49	-0.29	2.32	-3.08	0.73	1.83
Filing Date Shares Outstanding	206.62	205.89	205.31	153.33	128.24	127.96
Total Common Shares Outstanding	206.62	205.89	205.31	153.33	128.24	127.96
Working Capital	183.73	344.59	1,289	357.34	151.73	263.04
Book Value Per Share	10.15	11.89	15.13	12.43	9.45	8.61
Tangible Book Value	2,058	2,404	3,056	1,849	1,151	1,027
Tangible Book Value Per Share	9.96	11.68	14.88	12.06	8.98	8.03
Buildings	792.86	792.86	791.68	-	-	-
Machinery	1,602	1,603	1,575	837.57	688.02	573.33
Construction In Progress	158.31	106.85	3.35	624.35	260.37	164.56
Leasehold Improvements	317.34	317.34	307.77	276.23	246.21	236.3

Source: S&P Capital IQ. Standard template. Financial Sources.